Shanghai Pharma (SHPMY) 11.7900 $SHPMY
Shanghai Pharmaceuticals Released 2016 Q1 Results
JCN Newswire - Thu Apr 28, 7:36PM CDT
Shanghai Pharmaceuticals Released 2015 Annual Results: Operating Revenue Reached a New High of over 100 Billion for the First Time
JCN Newswire - Fri Mar 18, 8:56PM CDT
HONG KONG, Mar 19, 2016 - (ACN Newswire) - Shanghai Pharmaceuticals Holding Co., Ltd. ("Shanghai Pharmaceuticals" or the "Company" and, together with its subsidiaries, the "Group"; stock code: 601607.SH; 2607.HK), the integrated pharmaceutical company in the PRC that has leading positions in both pharmaceutical product and distribution markets, today released its annual report of 2015. According to the data, from January to December 2015, Shanghai Pharmaceutical's operating revenue was RMB105.517 billion, up by 14.20% on a YOY basis. Net profit attributable to the equity holders of listed Company was RMB2.877 billion, a YOY increase of 11.03%. Basic earnings per share amounted to RMB1.0699 and basic earnings per share after deducting non-recurring profits and losses were RMB0.9410, up by 17.08%, fulfilled the budget target for the year of 2015.
US$105 Million Shanghai Land Compensation Agreement
PR Newswire - Wed Dec 09, 1:00AM CST
Hutchison China MediTech Limited ("Chi-Med"
(AIM: HCM) today announces that Shanghai Hutchison Pharmaceuticals Limited ("SHPL", its 50:50 joint venture with a subsidiary of Shanghai Pharmaceuticals Holding Co., Limited, has today entered into an agreement (the "Agreement" with the Shanghai government for the surrender of SHPL's remaining 36 years land-use rights on its approximately 58,000 square metres old factory site at 2098 Zhennan Road, Taopu Town, Putuo District, Shanghai (the "Site".
HCM: 13.03 (+0.02)
Shanghai Pharmaceuticals Released 2015Q3 Results
JCN Newswire - Thu Oct 29, 10:18AM CDT
Shanghai Pharmaceuticals Holding Co., Ltd. ("Shanghai Pharmaceuticals" or the "Company" and, together with its subsidiaries, the "Group"; stock code: 601607.SH; 2607.HK), the integrated pharmaceutical company in the PRC that has leading positions in both pharmaceutical product and distribution markets, today released its third quarterly report of 2015. According to the data, from January to September 2015, Shanghai Pharmaceutical's operating revenue was RMB79.040 billion, up by 15.02% on a YOY basis. Net profit attributable to the equity holders of the parent company was RMB2.179 billion, representing a YOY increase of 13.92%. Net profit attributable to the equity holders of the parent company after deduction of nonrecurring profit or loss was RMB2.054 billion, representing a YOY increase of 20.39%, fulfilling the budget target for the third quarter of 2015.
Shanghai Pharmaceuticals and Jingdong Announced Comprehensive Strategic Cooperation in Strategies, Capital and Businesses
JCN Newswire - Mon May 18, 8:05AM CDT
Shanghai Pharmaceuticals Holding Co. Ltd., ("Shanghai Pharmaceuticals" or the "Company" and, together with its subsidiaries, the "Group"; stock code: 601607.SH; 02607.HK), announced on 17 May that the Company has entered into a strategic cooperative framework agreement with Beijing Jingdong Century Trading Co., Ltd. ("Jingdong". Pursuant to the agreement, both parties will establish comprehensive strategic cooperative partnership in three areas including strategies, capital and businesses with a view to grasping market and business opportunities, and achieving resources sharing and complementation of strengths.
Shanghai Pharmaceuticals Shows Strong Momentum in Both Revenue and Net Profit in First Quarter Off to a Good Start in 2015
JCN Newswire - Tue Apr 28, 3:22PM CDT
Shanghai Pharmaceuticals Holding Co. Ltd., ("Shanghai Pharmaceuticals" or the "Company" and, together with its subsidiaries, the "Group"; stock code: 601607.SH; 02607.HK), the integrated pharmaceutical company in the PRC that has leading positions in both pharmaceutical manufacture and distribution markets, today announced its first quarterly results. The Group recorded operating revenue of RMB25.125 billion, with an increase of 18.10% on a year-on-year basis. The net profit attributable to the shareholders of listed company was RMB733 million, with an increase of 25.08%. The net profit attributable to the shareholders of listed company after deduction of non-recurring items was RMB708 million, with an increase of 21.12% on a year-on-year basis. Revenues and profits soared significantly as compared with the same period of last year.
Shanghai Pharmaceuticals Invests to Set Up E-commerce Company; "Three Platforms, Three Layers of Networks"
JCN Newswire - Tue Mar 10, 9:58AM CDT
The integrated pharmaceutical company in the PRC that has leading positions in both pharmaceutical products and distribution markets - Shanghai Pharmaceuticals Holding Co., Ltd. ("Shanghai Pharmaceuticals" or the "Company" and, together with its subsidiaries, the "Group"; stock code: 601607.SH; 2607.HK) is pleased to announce that Shanghai Pharmaceuticals Greater Health Online Company is set up by Shanghai Pharmaceuticals and the e-commerce management team through co-investment in this drug e-commerce JV. The company is positioned to provide patients with the O2O sales of the prescription drugs, health management services and at the same time as e-commerce trader. In total, Shanghai Pharmaceuticals invested RMB 70 million while the e-commerce management team invested RMB 30 million to set up this new company.
Shanghai Pharmaceuticals Released 2016 Q1 Results
JCN Newswire - Thu Apr 28, 7:36PM CDT
Shanghai Pharmaceuticals Released 2015 Annual Results: Operating Revenue Reached a New High of over 100 Billion for the First Time
JCN Newswire - Fri Mar 18, 8:56PM CDT
HONG KONG, Mar 19, 2016 - (ACN Newswire) - Shanghai Pharmaceuticals Holding Co., Ltd. ("Shanghai Pharmaceuticals" or the "Company" and, together with its subsidiaries, the "Group"; stock code: 601607.SH; 2607.HK), the integrated pharmaceutical company in the PRC that has leading positions in both pharmaceutical product and distribution markets, today released its annual report of 2015. According to the data, from January to December 2015, Shanghai Pharmaceutical's operating revenue was RMB105.517 billion, up by 14.20% on a YOY basis. Net profit attributable to the equity holders of listed Company was RMB2.877 billion, a YOY increase of 11.03%. Basic earnings per share amounted to RMB1.0699 and basic earnings per share after deducting non-recurring profits and losses were RMB0.9410, up by 17.08%, fulfilled the budget target for the year of 2015.
US$105 Million Shanghai Land Compensation Agreement
PR Newswire - Wed Dec 09, 1:00AM CST
Hutchison China MediTech Limited ("Chi-Med"
(AIM: HCM) today announces that Shanghai Hutchison Pharmaceuticals Limited ("SHPL", its 50:50 joint venture with a subsidiary of Shanghai Pharmaceuticals Holding Co., Limited, has today entered into an agreement (the "Agreement" with the Shanghai government for the surrender of SHPL's remaining 36 years land-use rights on its approximately 58,000 square metres old factory site at 2098 Zhennan Road, Taopu Town, Putuo District, Shanghai (the "Site". HCM: 13.03 (+0.02)
Shanghai Pharmaceuticals Released 2015Q3 Results
JCN Newswire - Thu Oct 29, 10:18AM CDT
Shanghai Pharmaceuticals Holding Co., Ltd. ("Shanghai Pharmaceuticals" or the "Company" and, together with its subsidiaries, the "Group"; stock code: 601607.SH; 2607.HK), the integrated pharmaceutical company in the PRC that has leading positions in both pharmaceutical product and distribution markets, today released its third quarterly report of 2015. According to the data, from January to September 2015, Shanghai Pharmaceutical's operating revenue was RMB79.040 billion, up by 15.02% on a YOY basis. Net profit attributable to the equity holders of the parent company was RMB2.179 billion, representing a YOY increase of 13.92%. Net profit attributable to the equity holders of the parent company after deduction of nonrecurring profit or loss was RMB2.054 billion, representing a YOY increase of 20.39%, fulfilling the budget target for the third quarter of 2015.
Shanghai Pharmaceuticals and Jingdong Announced Comprehensive Strategic Cooperation in Strategies, Capital and Businesses
JCN Newswire - Mon May 18, 8:05AM CDT
Shanghai Pharmaceuticals Holding Co. Ltd., ("Shanghai Pharmaceuticals" or the "Company" and, together with its subsidiaries, the "Group"; stock code: 601607.SH; 02607.HK), announced on 17 May that the Company has entered into a strategic cooperative framework agreement with Beijing Jingdong Century Trading Co., Ltd. ("Jingdong"
. Pursuant to the agreement, both parties will establish comprehensive strategic cooperative partnership in three areas including strategies, capital and businesses with a view to grasping market and business opportunities, and achieving resources sharing and complementation of strengths. Shanghai Pharmaceuticals Shows Strong Momentum in Both Revenue and Net Profit in First Quarter Off to a Good Start in 2015
JCN Newswire - Tue Apr 28, 3:22PM CDT
Shanghai Pharmaceuticals Holding Co. Ltd., ("Shanghai Pharmaceuticals" or the "Company" and, together with its subsidiaries, the "Group"; stock code: 601607.SH; 02607.HK), the integrated pharmaceutical company in the PRC that has leading positions in both pharmaceutical manufacture and distribution markets, today announced its first quarterly results. The Group recorded operating revenue of RMB25.125 billion, with an increase of 18.10% on a year-on-year basis. The net profit attributable to the shareholders of listed company was RMB733 million, with an increase of 25.08%. The net profit attributable to the shareholders of listed company after deduction of non-recurring items was RMB708 million, with an increase of 21.12% on a year-on-year basis. Revenues and profits soared significantly as compared with the same period of last year.
Shanghai Pharmaceuticals Invests to Set Up E-commerce Company; "Three Platforms, Three Layers of Networks"
JCN Newswire - Tue Mar 10, 9:58AM CDT
The integrated pharmaceutical company in the PRC that has leading positions in both pharmaceutical products and distribution markets - Shanghai Pharmaceuticals Holding Co., Ltd. ("Shanghai Pharmaceuticals" or the "Company" and, together with its subsidiaries, the "Group"; stock code: 601607.SH; 2607.HK) is pleased to announce that Shanghai Pharmaceuticals Greater Health Online Company is set up by Shanghai Pharmaceuticals and the e-commerce management team through co-investment in this drug e-commerce JV. The company is positioned to provide patients with the O2O sales of the prescription drugs, health management services and at the same time as e-commerce trader. In total, Shanghai Pharmaceuticals invested RMB 70 million while the e-commerce management team invested RMB 30 million to set up this new company.
